In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upsher-Smith Laboratories LLC

Division of Sawai Pharmaceutical Co. Ltd.
www.upsher-smith.com

Latest From Upsher-Smith Laboratories LLC

Opioid Blister Packs Need Study Before Mandate, Groups Urge

AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.

Drug Safety Neurology

Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands

Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.

Value-Added Medicines Sales & Earnings

Sawai Eyes Global Position Helped By Growth In Japan And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Japan Business Strategies

Sawai Eyes Global Position Helped by Japan Growth And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Japan Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Upsher-Smith Laboratories Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sawai Pharmaceutical Co. Ltd.
  • Senior Management
  • Mark Evenstad, CEO
    Richard P Fisher, SVP, Corp. Strategy
    Sami Yusuf, VP, Corp. Dev.
  • Contact Info
  • Upsher-Smith Laboratories LLC
    Phone: (800) 654-2299
    6701 Evenstad Dr.
    Maple Grove, MN 55369
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register